CJC-1295 (no dac) 6mg + Ipamorelin 11mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of CJC-1295 / Ipamorelin Blend supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF112025089

Key analytical results include:

• Ipamorelin Assay Content: 11.09 mg
• Ipamorelin Identification – Retention Time: 0.998
• CJC-1295 (MOD GRF 1-29) Assay Content: 6.16 mg
• CJC-1295 Identification – Retention Time: 0.986
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

CJC-1295 / Ipamorelin is a dual-peptide research preparation combining two synthetic peptides frequently studied in controlled laboratory environments investigating endocrine signalling and peptide-receptor interaction systems.

The formulation combines CJC-1295 (MOD GRF 1-29), a modified analogue of growth hormone releasing hormone, with Ipamorelin, a synthetic peptide studied in relation to growth hormone secretagogue receptor signalling pathways.

This preparation contains a combined 17 mg of high purity lyophilized peptide material supplied in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the preparation for controlled in vitro experimentation.

Because of their defined peptide structures and verified analytical profiles, CJC-1295 and Ipamorelin are frequently referenced in experimental models investigating endocrine signalling and peptide-mediated receptor activation mechanisms.

Compound Overview

CJC-1295 (MOD GRF 1-29) is a modified analogue of growth hormone releasing hormone developed as a research compound to investigate hormone signalling pathways and receptor-mediated endocrine regulation.

Ipamorelin is a synthetic pentapeptide studied in biochemical research environments for its interaction with growth hormone secretagogue receptors and related peptide signalling networks.

Within laboratory research settings, both peptides are frequently investigated for their role in receptor-mediated signalling cascades and endocrine regulatory mechanisms.

The combination of these peptides within a single preparation allows researchers to study comparative signalling behaviour and peptide interaction dynamics within controlled experimental models.

Historical Background and Scientific Context

Scientific interest in hormone-regulating peptides increased significantly during the late twentieth century as advances in molecular biology enabled researchers to study endocrine signalling systems at the receptor level.

Growth hormone releasing hormone analogues such as CJC-1295 were developed as research tools to explore hormonal regulatory mechanisms and receptor signalling pathways.

Secretagogue peptides such as Ipamorelin were subsequently introduced to investigate receptor-mediated peptide signalling within endocrine systems.

Modern laboratory studies frequently examine combinations of peptides in order to analyse complex signalling interactions within endocrine regulatory networks.

Mechanistic Focus in Research

Within experimental laboratory environments, CJC-1295 / Ipamorelin blends are studied in relation to peptide-receptor interaction pathways and endocrine signalling mechanisms.

Research investigations commonly explore these peptides in experimental models examining:

• Growth hormone releasing hormone receptor signalling
• Growth hormone secretagogue receptor interaction
• Endocrine signalling pathway dynamics
• Peptide-mediated receptor activation mechanisms
• Intracellular signalling cascade modelling
• Comparative peptide interaction research
• Hormonal regulatory network analysis

These experimental models allow scientists to investigate molecular regulatory mechanisms influencing endocrine signalling and peptide-receptor interaction systems.

Research Applications

In controlled research environments, CJC-1295 / Ipamorelin blends may be utilised in experimental models designed to explore endocrine signalling systems and peptide-mediated receptor pathways.

Examples of research applications include:

• Endocrine signalling pathway investigation
• Peptide-receptor interaction research
• Hormonal regulatory mechanism studies
• Cell signalling analysis
• Comparative peptide interaction modelling
• Molecular endocrine pathway research
• Controlled in vitro peptide signalling studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

Verified and analysed with Liquilabs s.r.o. Czechia
Dual-peptide blend of CJC-1295 and Ipamorelin
Validated assay content 6.16 mg and 11.09 mg
No detectable heavy metals or microbial contamination
Endotoxin level below 0.001 EU per mg
Batch GF112025089 – Published January 2026
For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.